Is Omjjara (momelotinib) indicated for eligible adults with myelofibrosis who have never received a JAK inhibitor?

Yes, Omjjara (momelotinib) is indicated for disease-related splenomegaly or symptoms in JAK-inhibitor-naïve adults with moderate to severe anaemia and primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.